CCI
CBIO

Columbus Circle Investors’s Crescent Biopharma CBIO Stock Holding History

Columbus Circle Investors’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-5,611
Closed -$9.11M – 200
2018
Q1 		$9.11M Buy
5,611
+3,179
+131% +$6.61M 0.18% 138
2017
Q4 		$4.08M Buy
2,432
+412
+20% +$545K 0.08% 156
2017
Q3 		$2.83M Buy
2,020
+662
+49% +$777K 0.05% 207
2017
Q2 		$1.52M Buy
+1,358
New +$1.12M 0.03% 215

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Columbus Circle Investors's CBIO Position: Q2 2018 in Review

Columbus Circle Investors sold out of Crescent Biopharma (CBIO) in Q2 2018, closing a stake of 5,611 shares — an estimated $9.11M sold.

Columbus Circle Investors first reported a position in CBIO in Q2 2017 and held it in 4 quarters. The position peaked at $9.11M in Q1 2018. 84 funds tracked by Wall St. Rank hold CBIO as of Q2 2018.

  • Columbus Circle Investors reported no remaining Crescent Biopharma position as of Q2 2018 after selling out during the quarter.
  • Columbus Circle Investors sold 5,611 Crescent Biopharma shares in Q2 2018, an estimated $9.11M.
  • Columbus Circle Investors first reported a position in Crescent Biopharma in Q2 2017 and held it in 4 quarters.
  • Columbus Circle Investors's Crescent Biopharma position peaked at $9.11M in Q1 2018.
  • 84 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2018.

Based on Columbus Circle Investors's 13F filing for Q2 2018, filed 24 Jul 2018.